GSK Plc - HealthQuill

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

by HealthQuill
August 28, 2025
0 Comments

Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the Chinese company’s 12 potential medicines.

Drugs Health Pharma

GSK inks $500m deal with Jiangsu Hengrui for 12 potential medicines

HQ Team July 28, 2025: Britain’s GSK Plc will pay Jiangsu Hengrui Pharmaceuticals $500 million upfront to acquire global licensing rights for the.

by HealthQuill
July 28, 2025
0 Comments

GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract infections after the study achieved its goal on efficacy.

Drugs Health Pharma

GSK, Sepro end trial for oral drug to treat urinary tract infections

HQ Team May 28, 2025: GSK Plc. and Spero Therapeutics have stopped their combined trial of an investigational oral treatment for urinary tract.

by HealthQuill
May 28, 2025
0 Comments

Drugs Medical Pharma

GSK Plc’s drug to treat COPD gets clearance from US drug regulator

HQ Team May 24, 2025: The Food and Drug Administration has cleared GSK Plc’s drug for treating patients with inadequately controlled chronic obstructive.

by HealthQuill
May 24, 2025
0 Comments

GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2 billion in cash.

Drugs Health Pharma

GSK to buy Boston’s lead drug asset for liver disease for $2 billion in cash

HQ Team May 14, 2025: GSK Plc will acquire Boston Pharmaceutical’s investigational lead asset, efimosfermin alfa, to treat serious liver diseases, for $2.

by HealthQuill
May 14, 2025
0 Comments

Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple myeloma who have received at least one prior therapy.

Drugs Health Pharma

Britain gives green light for GSK Plc’s treatment of rare blood cancer

HQ Team April 18, 2025: Britain’s Medicines and Healthcare products Regulatory Agency has authorised GSK Plc’s combination drug to treat patients with multiple.

by HealthQuill
April 18, 2025
0 Comments

An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted infections in the world, according to the results of an end-stage study published in The Lancet.

Drugs Health Research

Oral antibiotic shows efficacy in end-stage trials to treat gonorrhoea

HQ Team April 16, 2025: An oral antibiotic, gepotidacin, has shown efficacy in fighting gonorrhoea — one of the most prevalent sexually transmitted.

by HealthQuill
April 16, 2025
0 Comments

The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in adult women and girls above 12 years, according to the company.

Drugs Medical Pharma

GSK’s drug to fight urinary tract infections gets USFDA approval

HQ Team March 26, 2025: The US Food and Drug Administration has approved Britain’s GSK Plc’s drug to treat urinary tract infections in.

by HealthQuill
March 26, 2025
0 Comments

GSK Plc will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.

Drugs Health Medical

GSK to pay Chimagen $300m upfront to develop autoimmune drug

GSK Plc., will pay China’s privately-held Chimagen Biosciences $300 million upfront to develop and commercialise a T-cell engager to treat autoimmune diseases.